These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21762696)

  • 1. Mutant ubiquitin (UBB+1) associated with neurodegenerative disorders is hydrolyzed by ubiquitin C-terminal hydrolase L3 (UCH-L3).
    Dennissen FJ; Kholod N; Hermes DJ; Kemmerling N; Steinbusch HW; Dantuma NP; van Leeuwen FW
    FEBS Lett; 2011 Aug; 585(16):2568-74. PubMed ID: 21762696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain.
    Fischer DF; De Vos RA; Van Dijk R; De Vrij FM; Proper EA; Sonnemans MA; Verhage MC; Sluijs JA; Hobo B; Zouambia M; Steur EN; Kamphorst W; Hol EM; Van Leeuwen FW
    FASEB J; 2003 Nov; 17(14):2014-24. PubMed ID: 14597671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin dimers control the hydrolase activity of UCH-L3.
    Setsuie R; Sakurai M; Sakaguchi Y; Wada K
    Neurochem Int; 2009; 54(5-6):314-21. PubMed ID: 19154770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing substrate selectivity of ubiquitin C-terminal hydrolase-L3 using engineered α-linked ubiquitin substrates.
    Navarro MF; Carmody L; Romo-Fewell O; Lokensgard ME; Love JJ
    Biochemistry; 2014 Dec; 53(51):8031-42. PubMed ID: 25369561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation.
    Lindsten K; de Vrij FM; Verhoef LG; Fischer DF; van Leeuwen FW; Hol EM; Masucci MG; Dantuma NP
    J Cell Biol; 2002 Apr; 157(3):417-27. PubMed ID: 11980917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes.
    Dang LC; Melandri FD; Stein RL
    Biochemistry; 1998 Feb; 37(7):1868-79. PubMed ID: 9485312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease.
    van Tijn P; de Vrij FM; Schuurman KG; Dantuma NP; Fischer DF; van Leeuwen FW; Hol EM
    J Cell Sci; 2007 May; 120(Pt 9):1615-23. PubMed ID: 17405812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubiquitin C-terminal hydrolase-L3 regulates EMT process and cancer metastasis in prostate cell lines.
    Song HM; Lee JE; Kim JH
    Biochem Biophys Res Commun; 2014 Sep; 452(3):722-7. PubMed ID: 25194810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin binding interface mapping on yeast ubiquitin hydrolase by NMR chemical shift perturbation.
    Rajesh S; Sakamoto T; Iwamoto-Sugai M; Shibata T; Kohno T; Ito Y
    Biochemistry; 1999 Jul; 38(29):9242-53. PubMed ID: 10413498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease-associated ubiquitin mutant Ubb
    Munari F; Bortot A; Assfalg M; D'Onofrio M
    Int J Biol Macromol; 2018 Mar; 108():24-31. PubMed ID: 29175520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing polyubiquitinated forms of the neurodegenerative ubiquitin mutant UBB
    Chojnacki M; Zhang D; Talarowska M; Gałecki P; Szemraj J; Fushman D; Nakasone MA
    FEBS Lett; 2016 Dec; 590(24):4573-4585. PubMed ID: 27861798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low levels of mutant ubiquitin are degraded by the proteasome in vivo.
    van Tijn P; Verhage MC; Hobo B; van Leeuwen FW; Fischer DF
    J Neurosci Res; 2010 Aug; 88(11):2325-37. PubMed ID: 20336771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death.
    De Vrij FM; Sluijs JA; Gregori L; Fischer DF; Hermens WT; Goldgaber D; Verhaagen J; Van Leeuwen FW; Hol EM
    FASEB J; 2001 Dec; 15(14):2680-8. PubMed ID: 11726544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cleavage of the C-terminus of NEDD8 by UCH-L3.
    Wada H; Kito K; Caskey LS; Yeh ET; Kamitani T
    Biochem Biophys Res Commun; 1998 Oct; 251(3):688-92. PubMed ID: 9790970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Length of the active-site crossover loop defines the substrate specificity of ubiquitin C-terminal hydrolases for ubiquitin chains.
    Zhou ZR; Zhang YH; Liu S; Song AX; Hu HY
    Biochem J; 2012 Jan; 441(1):143-9. PubMed ID: 21851340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for Monitoring "Ubiquitin C-Terminal Hydrolase 1" (Yuh1) Activity.
    Saad S; Berda E; Klein Y; Issa S; Pick E
    Methods Mol Biol; 2023; 2602():107-122. PubMed ID: 36446970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The ubiquitin-proteasome system and neurodegeneration].
    Wada K; Osaka H; Aoki S; Wang YL
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1072-4. PubMed ID: 12235799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate.
    Misaghi S; Galardy PJ; Meester WJ; Ovaa H; Ploegh HL; Gaudet R
    J Biol Chem; 2005 Jan; 280(2):1512-20. PubMed ID: 15531586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential role of ubiquitin c-terminal hydrolases in oncogenesis.
    Fang Y; Fu D; Shen XZ
    Biochim Biophys Acta; 2010 Aug; 1806(1):1-6. PubMed ID: 20302916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrate recognition and catalysis by UCH-L1.
    Luchansky SJ; Lansbury PT; Stein RL
    Biochemistry; 2006 Dec; 45(49):14717-25. PubMed ID: 17144664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.